{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:29:24Z","timestamp":1784330964046,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T00:00:00Z","timestamp":1497484800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10792-017-0605-4","type":"journal-article","created":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T03:04:57Z","timestamp":1497495897000},"page":"1741-1746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Topical bevacizumab treatment in aniridia"],"prefix":"10.1007","volume":"38","author":[{"given":"Ruth","family":"Lapid-Gortzak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie T. Y.","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla P.","family":"Nieuwendaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten P.","family":"Mourits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivanka J. E.","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,15]]},"reference":[{"issue":"6","key":"605_CR1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0039-6257(84)90184-X","volume":"28","author":"LB Nelson","year":"1984","unstructured":"Nelson LB, Spaeth GL, Nowinski TS, Margo CE, Jackson L (1984) Aniridia. A review. Surv Ophthalmol. 28(6):621\u2013642","journal-title":"Surv Ophthalmol."},{"issue":"2","key":"605_CR2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00003226-200303000-00004","volume":"22","author":"AM Tiller","year":"2003","unstructured":"Tiller AM, Odenthal MT, Verbraak FD, Gortzak-Moorstein N (2003) The influence of keratoplasty on visual prognosis in aniridia: a historical review of one large family. Cornea 22(2):105\u2013110","journal-title":"Cornea"},{"issue":"7","key":"605_CR3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1755-3768.2008.01293.x","volume":"86","author":"MF Paz de la","year":"2008","unstructured":"de la Paz MF, Alvarez de Toledo J, Barraquer RI, Barraquer J (2008) Long-term visual prognosis of corneal and ocular surface surgery in patients with congenital aniridia. Acta Ophthalmol 86(7):735\u2013740","journal-title":"Acta Ophthalmol"},{"issue":"7114","key":"605_CR4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature05249","volume":"443","author":"BK Ambati","year":"2006","unstructured":"Ambati BK, Nozaki M, Singh N et al (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature 443(7114):993\u2013997","journal-title":"Nature"},{"key":"605_CR5","first-page":"CD007325","volume":"10","author":"T Braithwaite","year":"2010","unstructured":"Braithwaite T, Nanji AA, Greenberg PB (2010) Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 10:CD007325","journal-title":"Cochrane Database Syst Rev"},{"key":"605_CR6","first-page":"CD005139","volume":"2","author":"SS Vedula","year":"2008","unstructured":"Vedula SS, Krzystolik MG (2008) Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2:CD005139","journal-title":"Cochrane Database Syst Rev"},{"key":"605_CR7","first-page":"CD007419","volume":"12","author":"G Virgili","year":"2012","unstructured":"Virgili G, Parravano M, Menchini F, Brunetti M (2012) Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 12:CD007419","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"605_CR8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","volume":"246","author":"F Bock","year":"2008","unstructured":"Bock F, Konig Y, Kruse F, Baier M, Cursiefen C (2008) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246(2):281\u2013284","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"605_CR9","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1167\/iovs.07-1129","volume":"50","author":"F Bock","year":"2009","unstructured":"Bock F, Onderka J, Rummelt C et al (2009) Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 50(5):2095\u20132102","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"605_CR10","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.clinthera.2015.08.023","volume":"37","author":"N Kasetsuwan","year":"2015","unstructured":"Kasetsuwan N, Reinprayoon U, Satitpitakul V (2015) Prevention of recurrent pterygium with topical bevacizumab 0.05% eye drops: a randomized controlled trial. Clin Ther 37(10):2347\u20132351","journal-title":"Clin Ther"},{"issue":"2","key":"605_CR11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/ICO.0b013e3182151e0e","volume":"31","author":"K Lekhanont","year":"2012","unstructured":"Lekhanont K, Patarakittam T, Thongphiew P, Suwan-apichon O, Hanutsaha P (2012) Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study. Cornea 31(2):155\u2013161","journal-title":"Cornea"},{"issue":"1","key":"605_CR12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ICO.0b013e3181822615","volume":"28","author":"PC Wu","year":"2009","unstructured":"Wu PC, Kuo HK, Tai MH, Shin SJ (2009) Topical bevacizumab eyedrops for limbal\u2013conjunctival neovascularization in impending recurrent pterygium. Cornea 28(1):103\u2013104","journal-title":"Cornea"},{"issue":"10","key":"605_CR13","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","volume":"247","author":"Y Koenig","year":"2009","unstructured":"Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C (2009) Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247(10):1375\u20131382","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"605_CR14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jprot.2013.09.003","volume":"94","author":"R Ihnatko","year":"2013","unstructured":"Ihnatko R, Eden U, Lagali N, Dellby A, Fagerholm P (2013) Analysis of protein composition and protein expression in the tear fluid of patients with congenital aniridia. J Proteomics 94:78\u201388","journal-title":"J Proteomics"},{"issue":"6","key":"605_CR15","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","volume":"48","author":"F Bock","year":"2007","unstructured":"Bock F, Onderka J, Dietrich T et al (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48(6):2545\u20132552","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"605_CR16","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","volume":"91","author":"RP Manzano","year":"2007","unstructured":"Manzano RP, Peyman GA, Khan P et al (2007) Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91(6):804\u2013807","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"605_CR17","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1111\/j.1755-3768.2012.02540.x","volume":"91","author":"L Asena","year":"2013","unstructured":"Asena L, Akova YA, Cetinkaya A, Kucukerdonmez C (2013) The effect of topical bevacizumab as an adjunctive therapy for corneal neovascularization. Acta Ophthalmol 91(3):e246\u2013e248","journal-title":"Acta Ophthalmol"},{"key":"605_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3928\/15428877-20100215-07","volume":"9","author":"A Galor","year":"2010","unstructured":"Galor A, Yoo SH (2010) Corneal melt while using topical bevacizumab eye drops. Ophthalmic Surg Lasers Imaging 9:1\u20133","journal-title":"Ophthalmic Surg Lasers Imaging"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-017-0605-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-017-0605-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-017-0605-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T01:27:54Z","timestamp":1692840474000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-017-0605-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,15]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["605"],"URL":"https:\/\/doi.org\/10.1007\/s10792-017-0605-4","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,15]]}}}